JABFM
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Green, B. B.
Right arrow Articles by Taplin, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Green, B. B.
Right arrow Articles by Taplin, S. H.
The Journal of the American Board of Family Practice 16:233-241 (2003)
© 2003 American Board of Family Practice


Clinical Review

Breast Cancer Screening Controversies

Beverly B. Green, MD, MPH and Stephen H. Taplin, MD, MPH

Center for Health Studies (BBG, SHT), Group Health Cooperative, Seattle
Department of Preventive Care (BBG, SHT), Group Health Cooperative, Seattle

Correspondence: Address reprint requests to Beverly B. Green MD, MPH, Department of Preventive Care, 1750 Minor Avenue, Suite 1600, Seattle, WA 98101-1448

Background: The Cochrane Collaborative, a respected independent review body, recently published a meta-analysis of the effectiveness of screening mammography in decreasing breast cancer mortality. Based on the results of two controlled trials they judged to be of medium validity, they concluded that screening mammography was unjustified. In contrast, the US Preventive Services Task Force recently updated their screening recommendations, and based on a meta-analysis of the same randomized controlled trials, they recommended screening mammography for all women starting at age 40 years. Additionally the Canadian Task Force on Preventive Health Care no longer recommends breast self-examination (BSE). This article reviews the controversies regarding breast cancer screening.

Methods: We performed a systematic review of the literature using keywords and cross-referencing articles. We also used automated data from the Breast Cancer Screening Program at Group Health Cooperative to determine the sensitivity of the clinical breast examination (CBE) at our institution. For the latter we included all cancers diagnosed within 1 year of a screening examination and then determined which of those had been found by CBE.

Results: Although most screening studies have shown that mammography decreases breast cancer death, there are controversies about the validity of some of the randomized controlled screening mammography trials. These controversies have led to different conclusions about the efficacy of screening mammography. Evidence is limited about the optimal interval for screening mammography. No studies have directly tested the efficacy of the CBE in decreasing breast cancer mortality. At Group Health Cooperative, 8% of all diagnosed breast cancers were found by the CBE alone (negative mammogram). Whether this 8% incremental increase in case finding leads to decreased breast cancer deaths is unknown. There is good evidence that training women to perform BSE does not increase breast cancer diagnoses or decrease breast cancer deaths.

Conclusion: There are limitations to randomized controlled trials and meta-analyses. The balance of the evidence still favors screening mammography in women aged 40 years and older at least every 2 years. The independent incremental benefit of the CBE, when added to mammography, in decreasing breast cancer mortality is unknown. Population-based education and training to do BSE are unlikely to lead to decreased breast cancer deaths. Many women find their own breast cancers, so women need to pay attention to symptoms or changes in their breasts.





This article has been cited by other articles:


Home page
JCOHome page
M. Koomen, E. D. Pisano, C. Kuzmiak, D. Pavic, and R. McLelland
Future Directions in Breast Imaging
J. Clin. Oncol., March 10, 2005; 23(8): 1674 - 1677.
[Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
N. Oestreicher, C. D. Lehman, D. J. Seger, D. S. M. Buist, and E. White
The Incremental Contribution of Clinical Breast Examination to Invasive Cancer Detection in a Mammography Screening Program
Am. J. Roentgenol., February 1, 2005; 184(2): 428 - 432.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
O. W. Brawley and B. S. Kramer
Cancer Screening in Theory and in Practice
J. Clin. Oncol., January 10, 2005; 23(2): 293 - 300.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Rao, P. S. Patel, S. P. Idler, P. Maloof, P. Gascon, J. A. Potian, and P. Rameshwar
Facilitating Role of Preprotachykinin-I Gene in the Integration of Breast Cancer Cells within the Stromal Compartment of the Bone Marrow: A Model of Early Cancer Progression
Cancer Res., April 15, 2004; 64(8): 2874 - 2881.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Board of Family Medicine.